Blueprint Medicines
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 655
- Market Cap
- $5.8B
- Introduction
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Expanded Access Program for Avapritinib
- Conditions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Blueprint Medicines Corporation
- Registration Number
- NCT04714086
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 279
- Registration Number
- NCT04697446
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
π«π·University Hospital Center of Toulouse - Larrey Hospital, Toulouse, France
π¨πLucerne Cantonal Hospital, Lucerne, Switzerland
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 317
- Registration Number
- NCT04695431
- Locations
- πΊπΈ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
π¬π§Guy's and St. Thomas' NHS Foundation Trust, London, England, United Kingdom
πͺπΈHospital Virgen del Valle, Toledo, Spain
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Blueprint Medicines Corporation
- Registration Number
- NCT04204928
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
- Conditions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Blueprint Medicines Corporation
- Registration Number
- NCT03862885
Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 108
- Registration Number
- NCT03858075
- Locations
- πΊπΈ
Undisclosed, Lincoln, Nebraska, United States
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
- Conditions
- Interventions
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 251
- Registration Number
- NCT03731260
- Locations
- πΊπΈ
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
π©πͺUniversity Clinic Hamburg Eppendorf, University Cancer Center Hamburg (UCCH), Hamburg, Germany
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
- Conditions
- Interventions
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 103
- Registration Number
- NCT03580655
- Locations
- π¨π¦
St. Michael's Hospital, Toronto, Ontario, Canada
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈUniversity of Texas, MD Anderson Cancer Center, Houston, Texas, United States
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 476
- Registration Number
- NCT03465722
- Locations
- πΊπΈ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
πΊπΈNorthwestern Medicine, Chicago, Illinois, United States
πΊπΈThe University of Chicago Medical Center, Chicago, Illinois, United States
Mast Cell Connect: A Registry for Patients With Mastocytosis
- Conditions
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 743
- Registration Number
- NCT02620254
- Locations
- πΊπΈ
Registry participation is worldwide and not limited to this facility, Cambridge, Massachusetts, United States